Strides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts more than Nifty Microcap 250 and 1.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science reported Q1 FY26 consolidated revenue from operations of Rs. 1,119.7 crore, up about 6.2% from the restated Rs. 1,054.3 crore in Q1 FY25. Profit before exceptional items and tax rose sharply to Rs. 130.3 crore (vs Rs. 83.7 crore), helped by lower finance costs. However, profit after tax from continuing operations fell to Rs. 105.6 crore (vs Rs. 161.5 crore YoY) because the prior year had a one-time gain on the CDMO/Softgel demerger of Rs. 31,881 million. Exceptional items of Rs. 8.4 crore this quarter relate mainly to product recall/settlement costs for Ranitidine, Losartan and Testosterone issues. Standalone revenue was Rs. 498.6 crore with PAT of Rs. 13.3 crore. The Board has proposed a final dividend of Rs. 4 per share (~Rs. 369 million outflow), subject to shareholder approval. B S R & Co. LLP issued an unmodified limited review opinion on both consolidated and standalone results.
Steady top-line growth and improved operating profitability are positives, but a high base in the year-ago quarter (boosted by a one-time demerger gain) makes the headline PAT look weak. Continued product recall expenses and the absence of the prior demerger gain may weigh on sentiment, though the proposed dividend and the demerged business appearing as discontinued operations gives a cleaner view of the ongoing pharma business going forward.